the aid library

LIST OPTIONS

Filter

7520

Download (303)

View PDF (277)

Inter-Agency Reproductive Health Kits 6th Edition - Manual

Inter-Agency Working Group on Reproductive Health in Crisis IAWG and UNFPA (2021) C1

Download (298)

View PDF (309)

Consensus Document for Management of Larynx and Hypopharynx Cancers

Indian Council of Medical Research (ICMR) (2017) C1

Prepared as an outcome of ICMR Subcommittee on Larynx & Hypopharynx Cancers | This consensus document on management of larynx and hypopharynx cancers summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and re... more

Download (96)

View PDF (95)

The Burden of Pediatric Asthma

Ferrante, G.; La Grutta, S. Frontiers in Pediatrics (2018) CC

Asthma is the most common chronic disease in children, imposing a consistent burden on health system. In recent years, prevalence of asthma symptoms became globally increased in children and adolescents, particularly in Low-Middle Income Countries (LMICs). Host (genetics, atopy) and environmental fa... more

Download (134)

View PDF (157)

Strategies and interventions on preventing and responding to violence and injuries among refugees and migrants (2020)

World Health Organization WHO (2020) C_WHO

This technical guidance outlines current evidence, knowledge and best practice relating to incidences of violence and injuries among refugees and migrants in the WHO European Region. It highlights key principles, summarizes priority actions and challenges, maps existing international commitments and... more

Download (176)

View PDF (150)

National hiv testing services communication strategy 2015 - 2019

National AIDS STI Control Programme (NASCOP), Ministry of Health, Government of Kenya (2015) C1

Strategic communication is used to raise awareness of issues among specific target populations. It aims to provide timely, evidence-based, authoritative information and guidance needed for public health action. Proper implementation of strategic communication leads t... more

Download (420)

View PDF (1322)

Spousal Violence and HIV: Exploring the Linkages in Five Sub-Saharan African Countries

MacQuarrie, Kerry L.D., Rebecca Winter, and Sunita Kishor ICF International (2013) C2

DHS Analytical Studies No. 36

Download (308)

View PDF (331)

WHO operational handbook on tuberculosis: module 2: screening: systematic screening for tuberculosis disease

World Health Organization WHO (2020) C_WHO

Download (379)

View PDF (309)

Community-facility Linkages to Support the Scale up of Lifelong Treatment for Pregnant and Breastfeeding Women Living with HIV: A Conceptual Framework, Compendium of Promising Practices and Key Operat

Ackerman Gulaid, Laurie United Nations Children’s Fund (UNICEF) (2015)

Download (281)

View PDF (612)

Haiti: Hurricane Matthew - Situation Report No. 22 (16 November 2016)

UN Office for the Coordination of Humanitarian Affairs (2016) C1

Main Points The delivery of humanitarian assistance is expected to slow down significantly over the next seven to ten days in anticipation of the electoral process and limited availability of transport and security assets. The percentage of extremely food-insecure people who have recei... more

Download (324)

View PDF (330)

HEARTS. Accès aux médicaments essentiels et aux technologies de santé de base

Organisation Mondiale de la Santé OMS, et al. (2018) C_WHO

Guide technique pour la prise en charge des maladies cardiovasculaires dans le cadre des soins de santé primaires

Download (1020)

View PDF (929)

Namibia: Nutrition guidelines for prevention and management of non-communicable diet related disease

Ministry of Health and Social Services (MOHSS) (2013) C1

Download (182)

View PDF (202)

Nurses as substitutes for doctors in primary care - Review

Laurant M, van der Biezen M, Wijers N et al. Cochrane Library (2018) CC

Current and expected problems such as ageing, increased prevalence of chronic conditions and multi-morbidity, increased emphasison healthy lifestyle and prevention, and substitution for care from hospitals by care provided in the community encourage countries worldwide to develop new models of prima... more

Download (590)

View PDF (1631)

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec... more

External Link

Environmental Determinants of Cardiovascular Disease

Bhatnagar, A. Circulation Research (2018) CC

Many features of the environment have been found to exert an important influence on cardiovascular disease (CVD) risk, progression, and severity. Changes in the environment due to migration to different geographic locations, modifications in lifestyle choices, and shifts in social policies and cultu... more

Download (346)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more